Catalyst Pharmaceuticals, Inc. (CPRX) News
Filter CPRX News Items
CPRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CPRX News Highlights
- CPRX's 30 day story count now stands at 5.
- Over the past 21 days, the trend for CPRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CPRX are DEC, DRUG and GAME.
Latest CPRX News From Around the Web
Below are the latest news stories about CATALYST PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CPRX as an investment opportunity.
Small Caps Are On A Tear Including Speculative BiotechsSo far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. |
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo PharmaCORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its collaboration partner, DyDo Pharma, Inc. ("DyDo"), reported that it has submitted a New Drug Application (“NDA”) to Japan's Pharmaceuticals and Medical Devices Agency (“PMDA”) seeking marketing approval |
7 Undervalued Biotech Stocks That are Flying Under the Clinical RadarWith so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. |
Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap CompaniesCatalyst Ranked #4 on the ListCORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024. Catalyst has ranked an impressive 4th out of 100 companies on this prestigious list, which recognizes small-cap companies that have demonstrated positive sales growth over the last twelve months. "We are very honored to b |
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive PromotionsMs. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective |
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare ConferenceCORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Piper Sandler 35th Annual Healthcare Conference taking place at the Lotte N |
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate UpdateThird Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $(0.29) Diluted, Impacted by an $81.5 Million One Time Non-Recurring IPR&D Expense Related to the Acquisition of AGAMREE® License Third Quarter 2023 Non-GAAP Net Income of $55.9 Million, $0.49 per Share Diluted Reported U.S. FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy sNDA Seeking to Increase FIRDAPSE® Maximum Daily Dose to 100 mg Accepted for Fili |
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent PortfolioCORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that the Company has received notification by the United States Patent and Trademark Office ("USPTO") that two |
Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 ReleaseAmylyx Pharmaceuticals, Inc. (AMLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |